SEC Form 4 · accession 0001127602-15-008627
UNITED THERAPEUTICS Corp · UTHR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Martine A Rothblatt
Officer — Chairman & Co-CEO · Director
Period of report
Feb 26, 2015
Accepted (ET)
Feb 26, 2015 · 5:10 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001082554
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Feb 26, 2015 | M | 5,547 | $30.75 | A | 5,787 | D | |
| Common StockF3 | Feb 26, 2015 | S | 2,101 | $154.566 | D | 3,686 | D | |
| Common StockF4 | Feb 26, 2015 | S | 2,746 | $155.4369 | D | 940 | D | |
| Common StockF5 | Feb 26, 2015 | S | 400 | $156.0825 | D | 540 | D | |
| Common Stock | Feb 26, 2015 | S | 100 | $157.00 | D | 440 | D | |
| Common StockF6 | Feb 26, 2015 | S | 200 | $158.47 | D | 240 | D | |
| Common StockF2 | Feb 26, 2015 | M | 4,115 | $34.56 | A | 4,355 | D | |
| Common StockF7 | Feb 26, 2015 | S | 4,115 | $155.1564 | D | 240 | D | |
| Common Stock | holding | — | — | — | 166 | I | By Spouse | |
| Common Stock | holding | — | — | — | 533,094 | I | By Trusts |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF2 | $30.75 | Feb 26, 2015 | M | 5,547 | D | Dec 26, 2009 | Dec 31, 2017 | Common Stock | 5,547 | 532,477 | D |
| Stock OptionsF2 | $34.56 | Feb 26, 2015 | M | 4,115 | D | Dec 30, 2005 | Dec 30, 2015 | Common Stock | 4,115 | 156,385 | D |
Explanation of responses
- F1This exercise of stock options and corresponding sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person.
- F2Exercise price and number of shares/awards has been adjusted to reflect the issuer's two-for-one stock split on September 22, 2009.
- F3This transaction was executed in multiple trades at prices ranging from $153.92 to $154.90. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4This transaction was executed in multiple trades at prices ranging from $154.94 to $155.93. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5This transaction was executed in multiple trades at prices ranging from $155.95 to $156.26. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6This transaction was executed in multiple trades at prices ranging from $158.41 to $158.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7This transaction was executed in multiple trades at prices ranging from $155.00 to $155.52. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.